Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Nonradiomimetic drugs, hydroxyurea (HU) and pipobroman (Pi), were administred to relatively young subjects with polycythemia vera (PV) in an attempt to decrease the leukemogenic risk observed in patients treated with 32P. Clinical safety, hematological efficacy, risk of carcinoma or leukemia, and frequency of progression to myelofibrosis have not yet been defined in long-term studies, and no comparative studies of HU and Pi have been conducted. Since 1980, 292 patients with PV diagnosed before the age of 65 years were randomized to receive treatment with HU (25 mg/kg/d, followed by low-dose maintenance) or Pi (1.2 mg/kg/d, followed by low-dose maintenance). Patients were followed until death or until May 1997. Drug tolerance was often poor; leg ulcers and buccal aphthous ulcers (with HU) and gastric pain and diarrhea (with Pi) sometimes required treatment change, mainly in the HU arm. Hematological stability, especially in terms of platelet count, was very often insufficient with HU (45% of cases), but the risk of thrombo-embolic event was similar in both arms. Actuarial survival was similar in the two arms and shorter than that of the reference population. The risk of leukemia was approximately 10% at the 13th year, with no significant difference between the two arms. The risk of carcinoma (when excluding the skin cancers) was similar in both groups. There was a high risk of progression to myelofibrosis in the patients treated by HU, which was significantly higher than with Pi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Estimates of the worldwide incidence of eighteen major cancers in 1985
Parkin, D. M., Pisani, P., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540413 · Cited by 1,638
WARD, H. P., & BLOCK, M. H. (1971) · Medicine · doi:10.1097/00005792-197109000-00001 · Cited by 524
Mechanism of action of hydroxyurea.
Yarbro, J. W. (1992) · PubMed · Cited by 407
Pearson, T. C., Guthrie, D. L., Simpson, J., Chinn, S., Barosi, G., Ferrant, A., Lewis, S. M., & Najean, Y. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08411.x · Cited by 321
Self-citationHuman megakaryocyte stimulation of proliferation of bone marrow fibroblasts
Castro-Malaspina, H., Rabellino, E., Yen, A., Nachman, R., & Moore, M. (1981) · Blood · doi:10.1182/blood.v57.4.781.781 · Cited by 281
Non-asbestos-related malignant mesothelioma. A review
Peterson, J. T., Greenberg, S. D., & Buffler, P. A. (1984) · Cancer · doi:10.1002/1097-0142(19840901)54:5<951::aid-cncr2820540536>3.0.co;2-a · Cited by 254
Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study.
Benson, A. B., Pregler, J. P., Bean, J. A., Rademaker, A. W., Eshler, B., & Anderson, K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2067 · Cited by 241
Yan, X., Lacey, D., Hill, D., Chen, Y., Fletcher, F., Hawley, R., & McNiece, I. (1996) · Blood · doi:10.1182/blood.v88.2.402.bloodjournal882402 · Cited by 202
Hydroxyurea therapy in children severely affected with sickle cell disease
Scott, J. P., Hillery, C. A., Brown, E. R., Misiewicz, V., & Labotka, R. J. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70335-9 · Cited by 174
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*
Löfvenberg, E., & Wåhlin, A. (1988) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1988.tb00212.x · Cited by 159
Weinfeld, A., Swolin, B., & Westin, J. (1994) · European Journal of Haematology · doi:10.1111/j.1600-0609.1994.tb01303.x · Cited by 158
Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice
Ulich, T., del Castillo, J., Senaldi, G., Kinstler, O. B., Yin, S., Kaufman, S., Tarpley, J. E., Choi, E. S., Kirley, T. L., Hunt, P., et al. (1996) · Blood · doi:10.1182/blood.v87.12.5006.bloodjournal87125006 · Cited by 109
Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy
Nocentini, G. (1996) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(95)00187-5 · Cited by 108
Informed consent in European multicentre randomised clinical trials — Are patients really informed?
Williams, C. J., & Zwitter, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90111-2 · Cited by 90
Boyd, A. S., & Neldner, K. H. (1991) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(91)70233-r · Cited by 89
Najean, Y., Dresch, C., & Rain, J. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb03289.x · Cited by 74
Self-citationSample size: how many patients are necessary?
Fayers, P., & Machin, D. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.268 · Cited by 69
Malignant mesothelioma following treatment for Hodgkin's disease.
Weissmann, L. B., Corson, J. M., Neugut, A. I., & Antman, K. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2098 · Cited by 61
Liozon, É., Brigaudeau, C., Trimoreau, F., Desangles, F., Fermeaux, V., Praloran, V., & Bordessoule, D. (1997) · Hematology and Cell Therapy · doi:10.1007/s00282-997-0011-x · Cited by 51
The ‘spent’phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis
Najean, Y., Arrago, J. P., Rain, J., & Dresch, C. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb01283.x · Cited by 39
Self-citationPrimary polycythaemia: diagnosis by non‐conventional positive criteria
Westwood, N., Dudley, J. M., Sawyer, B. M., et al. (1993) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1993.tb00636.x · Cited by 27
Cited by
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., et al. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.032 · Cited by 447
Metadata
- Authors
- Najean, Y., & Rain, J.-D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-11-01
- Volume
- 90
- Issue
- 9
- Pages
- 3370-3377
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1446966563
- Cited by
- 297
- References
- 23
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.